Biosimilars in inflammatory bowel diseases: An important moment for Brazilian gastroenterologists;Biosimilares nas doenças inflamatórias intestinais: Um momento importante para os gastroenterologistas brasileiros

Arquivos de Gastroenterologia

Volumn 52, Issue 1, 2015, Pages 76-80

  Teixeira, Fábio Vieira ^a   Kotze, Paulo Gustavo ^b   Damião, Aderson Omar Mourão Cintra ^c   Miszputen, Sender Jankiel ^d  

^a GASTROSAUDE Clinic   (Brazil)

^b HOSPITAL UNIVERSITÁRIO CAJURU   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biosimilar pharmaceuticals; Crohn disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; CD16 ANTIGEN; CERTOLIZUMAB PEGOL; FILGRASTIM; GOLIMUMAB; HUMAN GROWTH HORMONE; IMMUNOGLOBULIN G1 ANTIBODY; INFLIXIMAB; PROTEIN P55; PROTEIN P75; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; CROHN DISEASE; CYTOTOXICITY; DRUG MANUFACTURE; DRUG MECHANISM; ELECTROCARDIOGRAM; GASTROENTEROLOGIST; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; MOLECULAR INTERACTION; MOLECULAR WEIGHT; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; BRAZIL; COLITIS, ULCERATIVE; INFLAMMATORY BOWEL DISEASES; SYNTHESIS;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; BRAZIL; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84929615074     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032015000100016     Document Type: Article

References (33)

1. ANVISA. [Internet]. Registro de Produtos Biológicos. Bases Legais e Guias - Coletânea. Resolução - RDC n 55, de 16 de dezembro de 2010. Available from: http://portal.anvisa.gov.br/wps/wcm/connect/935aed0048bd2755a7cdaf9a6e94f0d0/ Registro_Produtos_Biologicos_Hemoterapicos_10102011_WEB. pdf?MOD=AJPERES.
2. Azevedo VF. Biossimilares necessitam de dados clínicos comparativos cientificamente confiáveis. Rev Bras Reumatol. 2013;53(1):127-31.
3. Biologics Price Competition and Innovation Act of 2009, H.R. 3590-687, Licensure of Biological Products as Biosimilar or Interchangeable. [Accessed 02.09.14]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ ucm216146.pdf
4. Biosimilar News. [Internet]. World's first biosimilar antibody is approved in Korea; 2012 Jul 23. [Accessed 2013 Ap 04]. Available from: http://www.biosimilarnews. com/worlds-first- biosimilar-antibody-is-approved-in-korea
5. Castanheira LG, Barbano DB, Rech N. Current development in regulation of similar biotherapeutic products in Brazil. Biologicals. 2011;39(5):308
6. Celltrion Healthcare Co. Ltd. [Internet]. INFLECTRA (infliximab). Product Monograph. [cited 2013 Ap 04]. Available from: http://fresenius-kabi.ca/en/ wp-content/uploads/sites/2/2014/04/Remsima_product-monograph.pdf
7. Celltrion Healthcare Co. Ltd. [Internet]. REMSIMA (infliximab). Product Monograph. [Accessed 2013 Ap 04]. Available from: http://fresenius-kabi.ca/en/ wp-content/uploads/sites/2/2014/04/Remsima_product-monograph.pdf
8. Chen, HA, Lin, KC, Chen, CH, Liao, HT, Wang, HP, Chang, HN, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:35-9.
9. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014;8(11):1548-50.
10. Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7(7):586e9.
11. Decleck PF. Biological and biosimilars: is similar the same? J Crohns Colitis. 2013;8:S427.
12. Devlin SM, Bressler B, Bernstein CN, Fedorak RN, Bitton A, Singh H, et al. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol. 2013;27(10):567e71.
13. European Medicines Agency recommends approval of first two monoclonal antibody biosimilars. [Internet]. Recommendation marks extension of biosimilar concept to new product-class. [Accessed 2013 Ap 04]. Available from: http:// www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/ WC500144941.pdf
14. European Medicines Agency. [Internet]. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use, November 2012. 2012 Nov 14. [Accessed 2013 Ap 04]. Available from: http:// ec.europa.eu/health/files/paediatrics/2012_report_paed_regulation.pdf.
15. European Medicines Agency. [Internet]. Biosimilar medicines. 2012. 2012 Nov 14. [Accessed 2013 Ap 04]. Available from: http://www.ema.europa.eu/ema/index. jsp?curl=pages/regulation/general/general_content_000408.jsp
16. European Medicines Agency. [Internet]. European Assessment Reports for authorized medicinal products for human use. 2012. 2012 Nov 14. [Accessed 2013 Ap 04]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/general/general_content_000433.jsp
17. Expert Committee on Biological Standardization, World Health Organization. [Internet]. Guidelines on evaluation of similar biotherapeutic products. [Accessed 2014 Ap 02]. Available from: http://www.who. int/biologicals/areas/biological_therapeutics/ BIOTHERAPEUTICS_FOR_WEB_ 22APRIL2010.pdf; 2009
18. Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42(4):177-83.
19. Gecse KB, Khanna R, van den Brink GR, Ponsioen CT, Löwenberg M, Jairath V, Travis SPL, Sandborn WJ, Feagan BG, D'Haens GRAM. Biosimilars in IBD: hope or expectation? Gut. 2013;62(6):803-7.
20. Ghosh S. Subsequent entry biologics e opportunities and challenges. Can J Gastroenterol. 2013;27(10):565.
21. Gramlick A, Fossati G, Nesbitt AM. Neutralization of soluble and membrane tumor necrosis factor-alpha (TNF- alpha) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-alpha receptor- specific bioassays. Gastroenterology. 2006;130(4):A697.
22. Guidance for Industry. [Internet]. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product. [Accessed 27.09.14]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceCompliance- RegulatoryInformation/Guidances/UCM397017.pdf
23. Health Canada. [Internet]. Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product: Inflectra. [Accessed 2013 Ap 04]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbdsmd/ drug-med/sbd_smd_2014_inflectra_159493-eng.php
24. Health Products and Food Branch, Health Canada. [Internet]. Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs). [Accessed 2014 Sept 27]. Available from: http://www.hc-sc.gc.ca/dhp-mps/ alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdf; 2010.
25. Janssen Biologics B.V. [Internet]. REMICADE (infliximab) summary of product characteristics. 2013. [Accessed 2014 Feb 01]. Available from: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/000240/WC500050888.pdf.
26. Korea Food and Drug Administration. National Institute of Food and Drug Safety Evaluation. Guidelines on the evaluation of biosimilar products. Chungcheongbuk- do: Korea Food and Drug Administration; 2010.
27. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J. 2013;16:22e6.
28. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19.
29. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605-12.
30. Scheinberg M. Biosimilars in Crohn's disease. J Crohns Colitis. 2014;8(7):71.
31. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-79.
32. Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of bio- similars: current status and future challenges. BioDrugs. 2013;27(3):203e11.
33. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT- P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613-20.